Theresa Hickman
Vanderbilt University(US)
Publications by Year
Research Areas
Virus-based gene therapy research, Cancer Research and Treatments, Viral Infectious Diseases and Gene Expression in Insects, Immunotherapy and Immune Responses, RNA Interference and Gene Delivery
Most-Cited Works
- → Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer(2013)762 cited
- → Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy(2011)143 cited
- → Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).(2013)14 cited
- → Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).(2013)9 cited
- → Erythrocyte membrane microviscosity and phospholipid composition in lead workers.(1987)7 cited
- → Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).(2012)4 cited
- → 124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA(2010)3 cited
- → A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).(2012)3 cited
- → Systemic inhibition of de novo purine biosynthesis prevents weight gain and improves metabolic health by increasing thermogenesis and decreasing food intake(2024)2 cited
- → P-187 Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer(2023)1 cited